Cargando…

Targeting stemness is an effective strategy to control EML4-ALK(+) non-small cell lung cancer cells

The fusion between anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) is a causative factor in a unique subset of patients with non-small cell lung carcinoma (NSCLC). Although the inhibitor crizotinib, as it blocks the kinase activity of the resulting EML4-A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Se Jin, Noh, Kyung Hee, Lee, Young-Ho, Hong, Soon-Oh, Song, Kwon-Ho, Lee, Hyo-Jung, Kim, Soyeon, Kim, Tae Min, Jeon, Ju-Hong, Seo, Jae Hong, Kim, Dong-Wan, Kim, Tae Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741893/ https://www.ncbi.nlm.nih.gov/pubmed/26517679

Ejemplares similares

EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Jin, Guang, et al.
Publicado: (2012)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive patients with lung cancer
por: Kim, Young Hun, et al.
Publicado: (2018)

Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive patients with lung cancer
por: Kim, Young Hun, et al.
Publicado: (2019)

Apoptosis inhibitor 5 increases metastasis via Erk-mediated MMP expression
por: Song, Kwon-Ho, et al.
Publicado: (2015)

Letter to the Editor: Detection of EML4-ALK and Other ALK Fusion Genes in Lung Cancer: A Lesson from the Leukemia Fusion Gene Analysis and Future Application
por: Park, Tae Sung, et al.
Publicado: (2012)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Interaction between SCP3 and JAB1 Confers Cancer Therapeutic Resistance and Stem-like Properties through EGF Expression
por: Oh, Se Jin, et al.
Publicado: (2021)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

API5 induces cisplatin resistance through FGFR signaling in human cancer cells
por: Jang, Han Sol, et al.
Publicado: (2017)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022)

EML4-ALK fusion gene in non-small cell lung cancer
por: Lei, Yu, et al.
Publicado: (2022)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
por: Bearz, Alessandra, et al.
Publicado: (2022)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
por: Jiang, Quan, et al.
Publicado: (2017)

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs
por: Cheon, So Yeong, et al.
Publicado: (2023)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
por: Ji, Jun Ho, et al.
Publicado: (2015)

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
por: Fukuyoshi, Y, et al.
Publicado: (2008)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
por: Sabir, Sarah R., et al.
Publicado: (2017)

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
por: Ijichi, Miharu, et al.
Publicado: (2022)

ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells
por: Schläfli, Anna M., et al.
Publicado: (2021)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
por: Thunnissen, Erik, et al.
Publicado: (2012)

EML4-ALK rearrangement of lung large cell neuroendocrine carcinoma: a case report
por: Chen, Dianjun, et al.
Publicado: (2023)

The availability of computed tomography for pulmonary staging in colorectal cancer
por: Oh, Bo-Young, et al.
Publicado: (2014)

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
por: von Buttlar, Xinyu, et al.
Publicado: (2021)

REP1 inhibits FOXO3-mediated apoptosis to promote cancer cell survival
por: Song, Kwon-Ho, et al.
Publicado: (2017)

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement
por: Choi, Se Hoon, et al.
Publicado: (2017)

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report
por: Yang, Hong, et al.
Publicado: (2022)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

The EML4-ALK oncogene: targeting an essential growth driver in human cancer
por: MANO, Hiroyuki
Publicado: (2015)

Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

Homing-Associated Cell Adhesion Molecules and Cell Cycle Status on the Nucleated Cells in the Bone Marrow, Mobilized Peripheral Blood and Cord Blood
por: Lee, Young-Ho, et al.
Publicado: (2004)

lincROR influences the stemness and crizotinib resistance in EML–ALK(+) non-small-cell lung cancer cells
por: Yang, Yonghua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kvobc2aej0mh31u10ik459n8og